Cannabis in Cancer Care — CINV, Pain, Cachexia, Palliative

The Strongest Evidence in Cancer Is for Symptom Relief Strong evidence

Cancer care is one of two areas — alongside chronic pain — where cannabis evidence earns the highest grade. The NASEM 2017 report rated the evidence for cannabinoids treating chemotherapy-induced nausea and vomiting (CINV) as "conclusive or substantial." This reflects decades of clinical use, FDA approvals, and inclusion in major oncology guidelines.

An essential clarification: the evidence supports cannabis for managing cancer symptoms — nausea, appetite loss, pain, and distress in palliative care. No human clinical trial has demonstrated that cannabis treats cancer itself.

FDA-Approved Cannabinoid Antiemetics

Two synthetic cannabinoids have received FDA approval as antiemetics for chemotherapy patients:

• Dronabinol (Marinol) — FDA-approved in 1985, a synthetic form of THC. Also approved for AIDS-related anorexia and weight loss.
• Nabilone (Cesamet) — FDA-approved in 2006, a synthetic cannabinoid structurally similar to THC. Specifically indicated for CINV in patients who have not responded adequately to conventional antiemetics.

Both medications are established in oncology practice. Their long track record provides the evidentiary foundation for the "strong" evidence rating — this is not a claim based on patient surveys or preclinical research, but on decades of clinical trial data and regulatory review.

Where Cannabinoids Fit in Current Guidelines

Current oncology guidelines from both the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) position cannabinoid antiemetics as breakthrough or rescue therapy after 5-HT3 antagonists — not first-line treatment. This means they are recommended when standard antiemetics (ondansetron, granisetron) are insufficient, not as the initial approach.

This positioning reflects the pharmacological reality that 5-HT3 antagonists are generally more effective as primary antiemetics, while cannabinoids fill a specific and valuable role for patients who continue to experience nausea despite first-line treatment.

The Unique Dual Benefit

Dr. Donald Abrams, Professor Emeritus of Medicine at UCSF and co-author of the 2024 ASCO Guideline on Cannabis and Cannabinoids in Adults with Cancer, has highlighted a pharmacological advantage unique to cannabinoids: cannabis is "the only antiemetic that also stimulates appetite."

This dual action matters because many cancer patients face both nausea and cachexia (severe weight loss and muscle wasting) simultaneously. Standard antiemetics address nausea but do nothing for appetite. The fact that cannabinoids can address both symptoms with a single agent is a meaningful clinical advantage, particularly for patients already managing complex medication regimens.

Appetite Loss, Cachexia, and Palliative Care

Beyond CINV, cannabis is widely used in cancer care for appetite stimulation and cachexia management. Dronabinol's FDA approval for AIDS-related anorexia provides a regulatory precedent for appetite stimulation, and the mechanism is relevant across conditions causing severe weight loss.

In palliative and end-of-life care, cannabis may serve multiple functions simultaneously: managing pain, improving appetite, reducing nausea, and easing anxiety. For patients in hospice or palliative settings, the risk-benefit calculation often shifts — the priority is comfort and quality of life, and concerns about long-term effects become less relevant.

For seniors in palliative care settings, see the Hospice & Palliative Care guide for practical information on cannabis use in end-of-life care.

Important Caveats for Seniors

Cancer patients considering cannabis should be aware of several specific concerns:

• Drug interactions with chemotherapy — CBD inhibits CYP3A4 and CYP2C9, enzymes that metabolize many chemotherapy drugs. Adding CBD to a chemotherapy regimen without oncologist approval could alter drug levels unpredictably. See the Drug Interactions Overview.
• Immunosuppression concerns — Some cancer treatments suppress immune function. Smoking or vaping cannabis introduces potential pathogens; if inhalation is preferred, vaporization of tested, dispensary-grade products is safer than smoking.
• "Cannabis cures cancer" claims are unfounded — While preclinical studies have explored anti-tumor properties of cannabinoids in cell cultures and animal models, no human clinical trial has demonstrated that cannabis cures, shrinks, or slows any cancer. Patients who delay or forgo conventional treatment in favor of cannabis risk worse outcomes.